Logo
x

Search category

Subscribe Now

Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

  • May 17, 2021
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

  • September 22, 2020
Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

  • August 31, 2020
Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria

Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria

  • September 25, 2019
Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) in India

Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal H...

  • August 16, 2019
Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults

Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria i...

  • July 4, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.